title: Suppression of experimental autoimmune uveitis in mice by induction of anterior chamber-associated immune deviation with interphotoreceptor retinoid-binding protein.
abstract: Immunization with bovine interphotoreceptor retinoid-binding protein induces autoimmune uveitis in B10.A mice. We have examined whether this soluble retina-specific Ag can induce anterior chamber-associated immune deviation when injected into the anterior chamber (AC) of the eye, and whether this deviant immune response has any effect on uveitis is susceptible mice. The results of these experiments indicate that interphotoreceptor retinoid-binding protein (IRBP) injected intracamerally altered the subsequent immune response of B10.A mice such that a) they were not able to develop IRBP-specific delayed hypersensitivity, nor (b) were they able to express significant autoimmune uveitis following a uveitogenic regimen. Moreover, spleen cells from mice that received IRBP in the AC suppressed uveitis when adoptively transferred into naive recipients. The splenic suppressor cells were able to prevent autoimmune uveitis in recipient mice when administered after the uveitogenic regimen. Most important, IRBP-specific splenic cells from mice treated with IRBP in the AC when injected into mice with established uveitis caused an abrupt cessation of the intraocular inflammation. The ability of intracamerally-injected soluble Ag to induce suppressor T cells that act on the efferent limb of the immune response suggests that the anterior-chamber-associated immune deviation phenomenon may have physiologic relevance in terms of preservation of the integrity of ocular tissue and renders this approach particularly suitable for treating already established experimental autoimmune diseases of this type. These results are discussed in terms of other methods that have been devised experimentally to suppress and prevent autoimmune uveitis and encephalomyelitis.
authors.affiliation: Department of Microbiology and Immunology, University of Miami School of Medicine, FL 33136.
authors.forename: Y
authors.initials: Y
authors.lastname: Hara
authors.forename: R R
authors.initials: RR
authors.lastname: Caspi
authors.forename: B
authors.initials: B
authors.lastname: Wiggert
authors.forename: C C
authors.initials: CC
authors.lastname: Chan
authors.forename: G A
authors.initials: GA
authors.lastname: Wilbanks
authors.forename: J W
authors.initials: JW
authors.lastname: Streilein
mesh_terms: D000818:Animals; D000867:Anterior Chamber / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology*; D005136:Eye Proteins / Q000008:administration & dosage / Q000276:immunology*; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007116:Immunization, Passive; D051379:Mice; D008815:Mice, Inbred Strains; D012177:Retinol-Binding Proteins / Q000008:administration & dosage / Q000276:immunology*; D013154:Spleen / Q000166:cytology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014605:Uveitis / Q000276:immunology* / Q000473:pathology; D000099214:Retinol-Binding Proteins, Interstitial
chemical_list: D005136:Eye Proteins; D012177:Retinol-Binding Proteins; D000099214:Retinol-Binding Proteins, Interstitial